01952 EVEREST MED-B
- 25.550
- +0.600+2.40%
EVEREST MED-B News
Genting Xinyao (01952.HK): Nifukang will soon start selling during the year, focus on the future volume of products
Genting Xinyao (01952.HK): Nifukang was approved for domestic listing, focusing on product release trends
Changes in Hong Kong stocks | Genting Xinyao once rose by more than 11%, Goldman Sachs raised its target price to HK$18.28
Bank Rating｜Goldman Sachs: Raising the target price of Genting Xinyao to HK$18.28 to maintain a “neutral” rating
Genting Xinyao B (01952.HK): Company transformation and commercialization volume are imminent, adhering to commercial introduction+self-development basic market
Research Report Nugge丨Huaan Securities: Genting Xinyao's core product, Nefecon Nefecon, will soon be approved for listing, maintaining a “buy” rating
Genting Xinyao (1952.HK) 2022 Report Review: The company's commercialization team is beginning to expand and enter the performance implementation period
Genting Xinyao (01952.HK): TRODELVY sells its interests in Asia and commercialization of various products is imminent
Genting Xinyao (1952.HK): Transferring TRODELVY's Asian interests to Gilead received US$455 million in consideration of the subsequent pipeline continued to gain strength
Genting Xinyao (01952.HK): Sales of TRODELVY Asia equity pipeline products are progressing smoothly
Genting Xinyao (1952.HK): Cash reserves increased after returning TRODELVY equity transactions
Genting Xinyao (1952.HK): 2022 Nuggets Summer and Autumn · Listed Company Exchange Meeting
Genting Xinyao B (1952.HK) follow-up review: The company's TROP2 ADC was approved for listing in the domestic FIRST IN CLASS
Genting Xinyao (1952.HK): Sales guidelines for the first TROP2 ADC approved in China exceeded expectations
Genting Xinyao-B (01952.HK): The LICENSE-IN+ self-developed model is moving towards commercialization and is committed to pioneering the world's first or best-in-class drug
Genting Xinyao (01952.HK): TRODELVY submitted a marketing application to actively deploy COVID-19 drugs
Genting Xinyao (1952.HK): Many products that consume less cash than expected in 2021 will soon be commercialized
Genting Xinyao (1952.HK): Introducing BTK inhibitors, foreign cooperation broadens pipeline R&D boundaries
Genting Xinyao (1952.HK): The introduction of the MRNA COVID-19 vaccine project is expected to be used as a booster vaccine in the future
Genting Xinyao (1952.HK): As commercialization approaches, 2-3 IN-LICENSING drugs are expected to be implemented in the near future
Analysis
Price Target
No Data
